炎症性肠病的肠道微生态变化及对策

李波; 孙杨; 缪应雷

doi:10.12259/j.issn.2095-610X.S20240401

炎症性肠病的肠道微生态变化及对策

doi: 10.12259/j.issn.2095-610X.S20240401

昆明医科大学第一附属医院消化内科/云南省消化系统疾病研究所/云南省消化系统疾病临床研究中心，云南昆明　650032

基金项目: 国家自然科学基金资助项目（U1802282；82060107）

详细信息

作者简介:
李波（2000～），女，白族，云南大理人，在读硕士研究生，主要从事炎症性肠病与肠道微生态研究工作

通讯作者:
缪应雷，E-mail：myldu@sina.com

中图分类号: R574
计量
- 文章访问数: 251
- HTML全文浏览量: 185
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2024-04-10
- 网络出版日期: 2024-04-21
- 刊出日期: 2024-04-29

Intestinal Microecological Changes and Therapeutics in Inflammatory Bowel Disease

Dept. of Gastroenterology，The 1st Affiliated Hospital of Kunming Medical University/Yunnan Institute of Digestive Disease/Yunnan Clinical Research Center for Digestive Diseases，Kunming Yunnan 650032，China

More Information

Corresponding author: 缪应雷，昆明医科大学第一附属医院主任医师，博士生导师，博士。国家百千万人才工程人选、国家有突出贡献中青年专家、国务院政府特殊津贴、云岭学者、云南省“名医”、云南省医学会消化病学分会-主任委员、国家临床重点专科负责人。主持国家自然科学基金6项（其中重点项目1项），获云南省政府颁发的省级科技进步一等奖2项，三等奖6项。以第一作者或通讯作者发表SCI论文47篇，其中以通讯作者在《Gastroenterology》（IF= 33.883）发表论著2篇、《Cell Host & Microbe》（IF=31.316）发表论著1篇。

摘要

摘要: 炎症性肠病（inflammatory bowel disease，IBD）是1种慢性疾病，其特征是反复发作的肠道炎症，尽管具体原因尚未完全明确，但普遍认为它是由遗传、免疫系统异常、环境因素和肠道微生物群失衡等多重因素共同作用引起的。这些因素的相互作用可能会导致肠道环境稳态受损，进而影响宿主的免疫，最终触发肠道炎症。综述IBD患者肠道微生物群的变化情况，并探讨相应的治疗对策。
- 炎症性肠病 /
- 肠道微生态 /
- 肠道菌群
Abstract: Inflammatory bowel disease （IBD） is a chronic condition characterised by recurrent inflammation of the intestines. Although the specific causes is not fully understood, it is generally believed to be caused by a combination of genetic factors, immune system abnormalities, environmental factors, and imbalances in the gut microbiota. The interaction of these factors may disrupt the intestinal environment, affecting the host's immune system, and ultimately triggering intestinal inflammation. This review discusses changes in the gut microbiota of IBD patients and explores corresponding treatment strategies.
- Inflammatory bowel disease /
- Intestinal microecological /
- Intestinal flora

HTML全文

图 1 基于肠道微生态的IBD治疗策略

Figure 1. Current microecological‐based therapeutic strategies in IBD

下载: 全尺寸图片幻灯片

参考文献(51)

[1]	Mak W Y,Zhao M,Ng S C,et al. The epidemiology of inflammatory bowel disease: East meets west[J]. Journal of Gastroenterology and Hepatology,2020,35(3):380-389. doi: 10.1111/jgh.14872
[2]	包云丽,汪哲,唐海茹,等. 1990-2019年中国炎症性肠病疾病负担及变化趋势分析[J]. 中国全科医学,2023,26(36):4581-4586.
[3]	Xu L,He B,Sun Y,et al. Incidence of inflammatory bowel disease in urban China: A nationwide population-based study[J]. Clinical Gastroenterology and Hepatology,2023,21(13): 3379-3386. e29.
[4]	Ng S C,Shi H Y,Hamidi N,et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies[J]. The Lancet,2017,390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0
[5]	Nakase H,Sato N,Mizuno N,et al. The influence of cytokines on the complex pathology of ulcerative colitis[J]. Autoimmunity Reviews,2022,21(3):103017. doi: 10.1016/j.autrev.2021.103017
[6]	Caparr ó s E,Wiest R,Scharl M,et al. Dysbiotic microbiota interactions in Crohn’ s disease[J]. Gut Microbes,2021,13(1):1949096. doi: 10.1080/19490976.2021.1949096
[7]	Lee M,Chang E B. Inflammatory bowel diseases (IBD) and the microbiome—Searching the crime scene for clues[J]. Gastroenterology,2021,160(2):524-537. doi: 10.1053/j.gastro.2020.09.056
[8]	Hu Y,Chen Z,Xu C,et al. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease[J]. Nutrients,2022,14(23):5140. doi: 10.3390/nu14235140
[9]	Schirmer M,Garner A,Vlamakis H,et al. Microbial genes and pathways in inflammatory bowel disease[J]. Nature Reviews Microbiology,2019,17(8):497-511. doi: 10.1038/s41579-019-0213-6
[10]	Kennedy J M,De Silva A,Walton G E,et al. A review on the use of prebiotics in ulcerative colitis[J]. Trends Microbiol,2023,Published online .
[11]	Li W,Sun Y,Dai L,et al. Ecological and network analyses identify four microbial species with potential significance for the diagnosis/treatment of ulcerative colitis (UC)[J]. BMC Microbiology,2021,21(1):138. doi: 10.1186/s12866-021-02201-6
[12]	Pittayanon R,Lau J T,Leontiadis G I,et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: A systematic review[J]. Gastroenterology,2020,158(4): 930-946. e1.
[13]	Waters J L,Ley R E. The human gut bacteria Christensenellaceae are widespread,heritable,and associated with health[J]. BMC Biology,2019,17(1):83. doi: 10.1186/s12915-019-0699-4
[14]	Hu W,Gao W,Liu Z,et al. Biodiversity and physiological characteristics of novel Faecalibacterium prausnitzii strains isolated from human feces[J]. Microorganisms,2022,10(2):297. doi: 10.3390/microorganisms10020297
[15]	Wang X,Ni J,You Y,et al. SNX10‐mediated LPS sensing causes intestinal barrier dysfunction via a caspase‐5‐dependent signaling cascade[J]. The EMBO Journal,2021,40(24):e108080. doi: 10.15252/embj.2021108080
[16]	Duerkop B A,Kleiner M,Paez-Espino D,et al. Murine colitis reveals a disease-associated bacteriophage community[J]. Nature Microbiology,2018,3(9):1023-1031. doi: 10.1038/s41564-018-0210-y
[17]	Zuo T,Lu X J,Zhang Y,et al. Gut mucosal virome alterations in ulcerative colitis[J]. Gut,2019,68(7):1169-1179. doi: 10.1136/gutjnl-2018-318131
[18]	Cao Z,Fan D,Sun Y,et al. The gut ileal mucosal virome is disturbed in patients with Crohn’ s disease and exacerbates intestinal inflammation in mice[J]. Nature Communications,2024,15(1):1638. doi: 10.1038/s41467-024-45794-y
[19]	Clooney A G,Sutton T D S,Shkoporov A N,et al. Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease[J]. Cell Host & Microbe,2019,26(6): 764-778. e5.
[20]	Ventin-Holmberg R,Eberl A,Saqib S,et al. Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease[J]. Journal of Crohn’ s and Colitis,2021,15(6):1019-1031. doi: 10.1093/ecco-jcc/jjaa252
[21]	Limon J J,Tang J,Li D,et al. Malassezia is associated with Crohn’ s disease and exacerbates colitis in mouse models[J]. Cell Host & Microbe,2019,25(3): 377-388. e6.
[22]	Rahabi M,Jacquemin G,Prat M,et al. Divergent roles for macrophage C-type lectin receptors,Dectin-1 and mannose receptors,in the intestinal inflammatory response[J]. Cell Reports,2020,30(13): 4386-4398. e5.
[23]	Torres J,Bonovas S,Doherty G,et al. ECCO guidelines on therapeutics in Crohn’ s disease: Medical treatment[J]. Journal of Crohn’ s & colitis,2020,14(1):4-22.
[24]	中华医学会消化病学分会炎症性肠病学组,中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南(2023年·西安)[J]. 中华炎性肠病杂志(中英文),2024,8(1):33-58.
[25]	中华医学会消化病学分会炎症性肠病学组,中国炎症性肠病诊疗质量控制评估中心. 中国克罗恩病诊治指南(2023年·广州)[J]. 中华炎性肠病杂志(中英文),2024,8(1):2-32.
[26]	Peters V,Bolte L,Schuttert E M,et al. Western and carnivorous dietary patterns are associated with greater likelihood of IBD development in a large prospective population-based cohort[J]. J Crohns Colitis,2022,16(6):931-939. doi: 10.1093/ecco-jcc/jjab219
[27]	Adolph T E,Meyer M,Schwärzler J,et al. The metabolic nature of inflammatory bowel diseases[J]. Nat Rev Gastroenterol Hepatol,2022,19(12):753-767. doi: 10.1038/s41575-022-00658-y
[28]	Narula N,Wong E C L,Dehghan M,et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: Prospective cohort study[J]. BMJ,2021,374:n1554.
[29]	Fritsch J,Garces L,Quintero M A,et al. Low-fat,high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis[J]. Clinical Gastroenterology and Hepatology,2021,19(6): 1189-1199. e30.
[30]	Wang S,Martins R,Sullivan M C,et al. Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids[J]. Microbiome,2019,7(1):126. doi: 10.1186/s40168-019-0740-4
[31]	Jakubczyk D,Leszczy ń ska K,G ó rska S. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)-A critical review[J]. Nutrients,2020,12(7):1973. doi: 10.3390/nu12071973
[32]	Sun M,Liu Y,Song Y,et al. The ameliorative effect of Lactobacillus plantarum-12 on DSS-induced murine colitis[J]. Food & Function,2020,11(6):5205-5222.
[33]	Yao S,Zhao Z,Wang W,et al. Bifidobacterium longum: Protection against inflammatory bowel disease[J]. Journal of Immunology Research,2021,2021:1-11.
[34]	Chen Y,Zhang M,Ren F. A role of exopolysaccharide produced by Streptococcus thermophilus in the intestinal inflammation and mucosal barrier in caco-2 monolayer and dextran sulphate sodium-induced experimental murine colitis[J]. Molecules,2019,24(3):513. doi: 10.3390/molecules24030513
[35]	Kang M,Choi H J,Yun B,et al. Bacillus amyloliquefaciens SCGB1 alleviates dextran sulfate sodium-induced colitis in mice through immune regulation[J]. Journal of Medicinal Food,2021,24(7):709-719. doi: 10.1089/jmf.2021.K.0044
[36]	Choi E J,Lee H J,Kim W J,et al. Enterococcus faecalis EF-2001 protects DNBS-induced inflammatory bowel disease in mice model[J]. PLoS One,2019,14(2):e0210854. doi: 10.1371/journal.pone.0210854
[37]	Tursi A,Brandimarte G,Papa A,et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind,randomized,placebo-controlled study[J]. American Journal of Gastroenterology,2010,105(10):2218-2227. doi: 10.1038/ajg.2010.218
[38]	Li S C,Hsu W F,Chang J S,et al. Combination of Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis shows a stronger anti-inflammatory effect than individual strains in HT-29 cells[J]. Nutrients,2019,11(5):969. doi: 10.3390/nu11050969
[39]	Dore M P,Rocchi C,Longo N P,et al. Effect of probiotic use on adverse events in adult patients with inflammatory bowel disease: A retrospective cohort study[J]. Probiotics and Antimicrobial Proteins,2020,12(1):152-159. doi: 10.1007/s12602-019-9517-0
[40]	Gibson G R,Hutkins R,Sanders M E,et al. Expert consensus document: The international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nature Reviews Gastroenterology & Hepatology,2017,14(8):491-502.
[41]	Wilson B,Eyice Ö,Koumoutsos I,et al. Prebiotic galactooligosaccharide supplementation in adults with ulcerative colitis: Exploring the impact on peripheral blood gene expression,Gut Microbiota,and Clinical Symptoms[J]. Nutrients,2021,13(10):3598. doi: 10.3390/nu13103598
[42]	Valcheva R,Koleva P,Mart í nez I,et al. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels[J]. Gut Microbes,2019,10(3):334-357. doi: 10.1080/19490976.2018.1526583
[43]	Ikegami S,Nakamura M,Honda T,et al. Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised,double-blind,placebo-controlled pilot study[J]. Alimentary Pharmacology & Therapeutics,2023,57(11):1249-1257.
[44]	Xue Z,Li R,Liu J,et al. Preventive and synbiotic effects of the soluble dietary fiber obtained from lentinula edodes byproducts and Lactobacillus plantarum LP90 against dextran sulfate sodium-induced colitis in mice[J]. Journal of the Science of Food and Agriculture,2023,103(2):616-626. doi: 10.1002/jsfa.12173
[45]	Amiriani T,Rajabli N,Faghani M,et al. Effect of Lactocare^® synbiotic on disease severity in ulcerative colitis: A randomized placebo-controlled double-blind clinical trial[J]. Middle East Journal of Digestive Diseases,2019,12(1):27-33. doi: 10.15171/mejdd.2020.160
[46]	Costello S P,Hughes P A,Waters O,et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial[J]. JAMA,2019,321(2):156. doi: 10.1001/jama.2018.20046
[47]	Haifer C,Paramsothy S,Kaakoush N O,et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): A randomised,double-blind,placebo-controlled trial[J]. Lancet Gastroenterol Hepatol,2022,7(2):141-151. doi: 10.1016/S2468-1253(21)00400-3
[48]	Boicean A,Birlutiu V,Ichim C,et al. Fecal microbiota transplantation in inflammatory bowel disease[J]. Biomedicines,2023,11(4):1016. doi: 10.3390/biomedicines11041016
[49]	Xu Z,Dong X,Yang K,et al. Association of adherent-invasive Escherichia coli with severe gut mucosal dysbiosis in Hong Kong Chinese population with Crohn’ s disease[J]. Gut Microbes,2021,13(1):1994833. doi: 10.1080/19490976.2021.1994833
[50]	Galtier M,De Sordi L,Sivignon A,et al. Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’ s disease[J]. Journal of Crohn’ s and Colitis,2017,11(7):jjw224.
[51]	Federici S,Kredo-Russo S,Valdés-Mas R,et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation[J]. Cell,2022,185(16): 2879-2898. e24.

相关文章(20)

[1]	李章琴, 黄奇, 缪应雷. 生物制剂在炎症性肠病治疗中的矛盾性肠外表现研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240223
[2]	牛俊杰, 姬文娟, 于拽拽. 肠道菌群、血清ET、PCT水平与脓毒症病情程度、预后的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240420
[3]	李媛媛, 宋亚贤, 徐玉善, 曾晓甫, 袁惠, 徐兆, 江艳. 肠道菌群代谢物TMAO与非酒精性脂肪性肝病的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240210
[4]	李春, 周琼, 梅聪, 黄洁杰, 王毅鹏, 周松兰, 郑倩, 唐哲. 双歧杆菌三联活菌对小鼠非酒精性脂肪肝模型中肠道微生物组的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231022
[5]	徐琳, 高开成, 贾杰, 李煜阳, 王华伟, 况轶群, 赵昱. 参苓白术散对甲基苯丙胺诱导小鼠肠道菌群改变的作用机制研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230829
[6]	邓绍友, 赵玉兰, 王佩锦, 李蓉, 李进涛, 郑红. 恒古骨伤愈合剂联合广谱抗生素改善db/db小鼠胰岛素抵抗和肠道菌群, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230530
[7]	梁彩红, 孟明耀, 李欣欣, 熊晶晶, 李檬, 刘梅, 侯宗柳, 黄永坤. 肠道菌群代谢物脱氧胆酸对人脐带间充质干细胞hUC-MSCs增殖及细胞周期的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230402
[8]	李丹, 万绪莲, 李律宇, 云宇, 罗光云, 刘韦兵, 林公府, 李宁, 黎勇坤, 段为钢. 尿酸酶缺失大鼠肠道菌群的变化, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230205
[9]	李露, 田云粉. 肠道菌群与儿童非酒精性脂肪性肝病的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230708
[10]	杨顺航, 李炯明, 刘建和, 王光, 李沛. 肠源性高草酸尿症的发病机制与治疗进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220734
[11]	阮艳琴, 李茂涓, 和丽梅, 宋莹, 黄巧云, 陈莹, 刘畅. 以患者为主的炎症性肠病患者PRO量表特异模块条目筛选, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220310
[12]	刘蓉, 孙杨, 罗发梦, 陶德智, 张海燕. 炎症性肠病患者疾病接受度与生存质量的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220507
[13]	郭艳东, 洪汝丹, 汪艳蛟, 张腾, 冯月梅, 张霓裳, 钱映, 杨早改, 米飞, 殷建忠. 培哚普利对肥胖大鼠肠道微生态的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221101
[14]	刘四香, 黄永坤, 王明英, 胡红卫, 马敏, 凌昱. 功能性便秘患儿的肠道菌群分析及治疗干预, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220309
[15]	戴海龙, 王南, 陈晓晴, 何臻一, 冯晓岚, 光雪峰. 冠心病患者肠道菌群的特征, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201213
[16]	唐娟, 念馨. 肠道微生态与肥胖相关性研究进展, 昆明医科大学学报.
[17]	梁睿, 淳于纬训, 沈焘, 孙乐, 李云峰. 肠道菌群和免疫在结直肠肿瘤中作用研究进展, 昆明医科大学学报.
[18]	薛平燕, 江艳, 徐玉善, 袁惠, 李璇, 宋亚贤, 刘华. 肠道菌群结构在非酒精性脂肪性肝病患者中的改变, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201120
[19]	王瑞涛, 贾庆安, 牟怡平, 耿智敏, 刘昌. 胆宁片调节肠道菌群移位消除胆道炎症及预防胆石形成的临床评价, 昆明医科大学学报.
[20]	张安兴, 吴静, 孙杨, 缪应雷. 炎症性肠病宿主遗传变异与肠道微生物的联系, 昆明医科大学学报.